scholarly journals Comparison of Survey Modality and Response Rate in Dermatologists’ Perceptions and Opinions of Sunscreens

2018 ◽  
Vol 2 (2) ◽  
pp. 122-126
Author(s):  
Alex M Glazer ◽  
Aaron S Farberg ◽  
Ryan M Svoboda ◽  
Darrell S Rigel
Keyword(s):  
Response Rate ◽  
Sun Exposure ◽  
Response Rates ◽  
Target Population ◽  
Vitamin D Supplementation ◽  
Audience Response ◽  
Variable Response ◽  
Significant Difference ◽  
Different Response ◽  
Scientific Survey

Background. Survey instruments are valuable tools for research and provide insight into real-world practice and areas of knowledge deficits in ways that traditional observational studies and randomized trials cannot. Despite some experts espousing survey response rates ≥60% as valid, there is no consensus as to what an adequate response rate is for a scientific survey. Furthermore, little is known what effect the interaction of survey administration modality and response rate has on results. Objective. To compare the results of differing survey modalities (which typically feature different response rate ranges). Methods. A validated, 21-item survey assessing perceptions of, recommendations regarding, and usage of sunscreen was distributed to three samples of dermatologists using three different modalities: pen/paper via mail, online via email, and in real-time via an audience response system at a national conference. Results. Response rates varied widely by survey modality (30% mail, 9% email 95% live). However, dermatologists’ responses to individual survey questions were largely consistent across modalities, with a statistically significant difference seen for only three questions (recommending sunscreens based on cosmetic elegance, recommending sunscreens based on photostability, and recommending vitamin D supplementation as a means to avoid sun exposure.  Conclusions. In this study evaluating dermatologists’ perceptions of, recommendations for, and personal use of sunscreen, survey results were largely consistent across three different modalities (mail, email, live) despite widely variable response rates, from 9% to 95%. These results suggest that when a scientific survey sample is representative of the target population, minimum response rate and survey modality appear to have negligible impact on results.

Provinciale responsverschillen in het Vlaamse Bevolkingsonderzoek Dikkedarmkanker: inzichten uit gemeentelijke socio-demografische en gezondheidsgerelateerde kenmerken

2021 ◽  
Author(s):  
T.N. TRAN ◽  
G. VAN HAL ◽  
M. PEETERS ◽  
S. JIDKOVA ◽  
S. HOECK
Keyword(s):  
Colorectal Cancer ◽  
Response Rate ◽  
Response Rates ◽  
Target Population ◽  
Wilcoxon Test ◽  
Future Research ◽  
Screening Methods ◽  
Average Income ◽  
Medical File ◽  
Crc Screening

Municipal characteristics associated with response rate to organised colorectal cancer screening in Flanders Introduction In Flanders (Belgium), the response rate to organised colorectal cancer (CRC) screening is still suboptimal (~ 50%). We studied the characteristics of municipalities in the Flemish provinces with the highest and lowest response rates to explore factors that might be associated with the response rate to organised CRC screening. Methods The response rates of municipalities in 5 Flemish provinces and the characteristics of municipalities in the provinces with the highest and lowest response rates were compared to the average measures of Flanders (data 2017) using an unpaired two-sample Wilcoxon test. Results The municipal response rates in Limburg and Antwerp were significantly higher, and those in West Flanders and Flemish Brabant significantly lower compared to Flanders. Further analyses of Limburg (highest response rate) and Flemish Brabant (lowest response rate) suggested that municipalities with higher response rates had more men and people aged 60-64 in the target population, more jobseekers and more people who contacted GPs/specialists frequently, but fewer people aged 70-74 in the target population and with a lower average income compared to Flanders. In contrast, municipalities with lower response rates had fewer men in the target population, fewer people having a partner, fewer jobseekers and fewer people having a global medical file, but more people with a non-Dutch or non-Belgian nationality and a higher average income (p-values < 0.01). Conclusion This exploratory study identifies certain demographic, socioeconomic and health‑related municipal characteristics that may be related to the response rate to CRC screening in Flanders. These findings can guide future research and investigations with the aim to improve the response rate to CRC screening.

scholarly journals Effect of Recruitment Methods on Response Rate in a Web-Based Study for Primary Care Physicians: Factorial Randomized Controlled Trial (Preprint)

2017 ◽  
Author(s):  
Ryuhei So ◽  
Kiyomi Shinohara ◽  
Takuya Aoki ◽  
Yasushi Tsujimoto ◽  
Aya M Suganuma ◽  
...  
Keyword(s):  
Primary Care ◽  
Primary Care Physicians ◽  
Response Rate ◽  
Controlled Trial ◽  
Response Rates ◽  
Risk Difference ◽  
Web Based ◽  
Subject Line ◽  
Significant Difference ◽  
The Subject

BACKGROUND Low participation rates are one of the most serious disadvantages of Web-based studies. It is necessary to develop effective strategies to improve participation rates to obtain sufficient data. OBJECTIVE The objective of this trial was to investigate the effect of emphasizing the incentive in the subject line of the invitation email and the day of the week of sending the invitation email on the participation rate in a Web-based trial. METHODS We conducted a 2×2 factorial design randomized controlled trial. We contacted 2000 primary care physicians from members of the Japan Primary Care Association in January 2017 and randomly allocated them to 1 of 4 combinations of 2 subject lines (presence or absence of an emphasis on a lottery for an Amazon gift card worth 3000 yen or approximately US $30) and 2 delivery days (sending the invitation email on Tuesday or Friday). The primary outcome was the response rate defined as the number of participants answering the first page of the questionnaire divided by the number of invitation emails delivered. All outcomes were collected between January 17, 2017, and February 8, 2017. RESULTS We analyzed data from 1943 out of 2000 participants after excluding those whose email addresses were invalid. The overall response rate was 6.3% (123/1943). There was no significant difference in the response rates between the 2 groups regarding incentive in the subject line: the risk ratio was 1.12 (95% CI 0.80 to 1.58) and the risk difference was 0.7% (95% CI –1.5% to 2.9%). Similarly, there was no significant difference in the response rates between the 2 groups regarding sending the email on Tuesday or Friday: the risk ratio was 0.98 (95% CI 0.70 to 1.38) and the risk difference was –0.1% (95% CI –2.3% to 2.1%). CONCLUSIONS Neither emphasizing the incentive in the subject line of the invitation email nor varying the day of the week the invitation email was sent led to a meaningful increase in response rates in a Web-based trial with primary care physicians. CLINICALTRIAL University Hospital Medical Information Network Clinical Trials Registry UMIN000025317; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029121 (Archived by WebCite at http://www.webcitation. org/6wOo1jl9t)

scholarly journals A110 PATIENT-GUIDED COMPLICATION TRACKING SYSTEM (PACTS): BUILDING ALLIANCES WITH PATIENTS FOR THE CONTINUED IMPROVEMENT OF POST-PROCEDURAL OUTCOMES.

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 87-89
Author(s):  
L Calman T’ien ◽  
C A Macdonnell ◽  
J Yonge ◽  
C Galorport ◽  
R A Enns
Keyword(s):  
Response Rate ◽  
Tracking System ◽  
Response Rates ◽  
Future Research ◽  
Median Response ◽  
Design Elements ◽  
Design Changes ◽  
Significant Difference ◽  
Message Service

Abstract Background In Healthcare, interventions using Short Message Service (SMS) are growing as more patients have mobile phones. To date, studies have investigated using SMS to remind patients of upcoming appointments and provide preventative medical care. Although SMS interventions exist, little is known about their potential as a post-procedural follow-up tool. SMS follow-up systems present a unique opportunity for clinics to provide support to patients having unplanned post-procedural events. Moreover, the identification of these cases promotes the adoption of preventative measures. Before SMS follow-up programs can be integrated in clinics, proof-of-concept research needs to be conducted to assess the feasibility of this intervention. Aims This study aims to determine intervention design elements to maximize the response rate of a novel follow-up program implemented at St. Paul’s Hospital in Vancouver, BC. Methods An iterative prospective study was conducted to assess the effects of various design features on the response rate of an SMS follow-up system. Outpatients having a colonoscopy and/or gastroscopy at St. Paul’s Hospital between 11/19-03/20 were considered for inclusion in this pilot. Patients were asked to participate if they understood Grade 10-level English and had a mobile phone. For this pilot, a PAtient-guided Complication Tracking System (PACTS) was designed to send SMS to patients one week post-procedure. During each program round, adjustments were made to PACTS with the goal of increasing the response rate. The design changes made to the pilot were cumulative. One-way ANOVA and Tukey’s Honestly Significant Difference tests were completed to assess response rate differences between rounds. Results A total of 1829 patients met the inclusion criteria and consented to participate in the pilot. The overall median response rate was 93%. ANOVA test revealed a statistically significant difference in response rates between rounds, F(6, 196) = 3.369, p = 0.0035. Only the mean response rates between Rounds 1 and 7 yielded a significant pairwise difference (p &lt; 0.001). Conclusions The PACTS pilot demonstrates that high response rates are achievable by SMS follow-up systems. This study identified several design elements to optimize SMS intervention response rates. These features included: sending a 1st SMS that explains the program’s purpose, sending a 2nd SMS to participants that did not respond to the first, and providing pilot information to patients upon admission and discharge. Future research on SMS follow-up systems should explore designing a program that can be integrated in clinics with minimal staff involvement. Funding Agencies None

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 522-522 ◽  
Author(s):  
S. Park ◽  
C. Kelaidi ◽  
S. Grabar ◽  
O. Beyne-Rauzy ◽  
S. Cheze ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Predictive Factors ◽  
Response Rate ◽  
Response Duration ◽  
Response Rates ◽  
Multilineage Dysplasia ◽  
Major Response ◽  
Significant Difference ◽  
The Impact

Abstract Background: EPO and its derivative darbepoietin alfa (DAR) are important treatments of anemia in lower risk MDS. Prognostic factors of response and of its duration have been recently updated (Blood, 2005, 106, 803–11) and we reanalyzed them in a large series of patients (pts) treated in France and Belgium. Patients: 419 MDS pts were treated with EPO (≥30000UI/wk for at least 12 wks) or DAR (300μg/wk)± GCSF in 25 GFM centers between 1998 and 2006 (160 prospectively analyzed in 3 consecutive trials, and 259 retrospectively analyzed). Median follow-up was 54 months, median age: 73.5 years. WHO classification: RA (14%), RCMD (16%), 5q- syndrome (4%), RARS (21%) RCMD-RS (13%), RAEB-1 (22%), RAEB-2 (6%), and also 4%CMML (FAB); karyotype: 64% FAV, 16% INT, and 4% UNFAV (16% failure or not done). IPSS: 34% LOW, 40% INT-1, 8% INT-2, 2% HIGH (16% unavailable). 185, 126, 80 and 28 pts received EPO alone (alfa or beta), DAR, EPO+G and DAR+G respectively. Median pre-treatment EPO level was 76 UI/l (only 7% pts>500 UI/l). All pts had Hb<10g/dl and 54% required RBC transfusions (including 36% with >2 RBC units/month). Results: 63% pts responded (IWG criteria: 43%HI-E major and 20% HI-E minor), including 57%, 63%, 57%, 66%, 63% with EPO alfa alone, beta alone, EPO+G, DAR alone, DAR+G response (p=ns). Median response duration was 20 mos (range 3–74 mos), 25 and 14 mos for major and minor responses (p= 0.001). Relapse was associated with treatment discontinuation (45%), progression to higher grade MDS (12%) or AML (13%), but without evident cause in 30% cases. In univariate analysis, significantly higher response rates were observed in pts with <10% blasts (p= 0.002), low and INT-1 IPSS score (p=0.001), transfusion <2 RBC units/month (p<0.0001), EPO level<200UI/l (p<0.0001) whereas no significant difference in response rate were seen between RA (69%,) RCMD (72%), RARS (59%), RCMD-RS (71%), RAEB-1 (60%) and 5q- syndrome (52%), and between cytogenetic groups. The response rate in RARS and RCMD-RS was similar with EPO or DAR alone (62.5%), and EPO or DAR+G (60%). In multivariate analysis, EPO <200UI/l (p=0.008), transfusion requirement (p<0.0001) and IPSS (p=0.047) remained predictive factors of response. Longer response duration was significantly associated with blasts<10% (20 mos vs 8 mos for blasts>10%, p=0.007), major response (vs minor), IPSS low-INT-1 (median 22 mos vs 8 mos for INT-2/HIGH, p=0.001) and in pts with absence of multilineage dysplasia (24 mos vs 16 mos, p=0.01). In multivariate analysis, blasts <10% and major response remained predictive factors of longer response. Conclusions: EPO level <200UI/l, RBC transfusions <2 units/month were confirmed as major prognostic factors of response to EPO±G. Good response rates were seen in RAEB-1, and with EPO alone, in RARS and RCMD-RS. Multilineage dysplasia was not associated with lower response rates, but with shorter response duration. Other prognostic factors of shorter response duration were minor response (vs major), and blasts >10%. A case control study with pts of the International MDS risk Analysis Workshop, who received RBC transfusion alone, is in progress to evaluate the impact of EPO treatment on leukemia-free survival and overall survival, and its results will be presented.

Response Rates and Perceived Questionnaire Length in Mail Surveys

1979 ◽  
Vol 16 (3) ◽  
pp. 429-431 ◽  
Author(s):  
Terry L. Childers ◽  
O. C. Ferrell
Keyword(s):  
Interaction Effect ◽  
Response Rate ◽  
Mail Survey ◽  
Response Rates ◽  
Survey Response ◽  
Factorial Experiment ◽  
Mail Surveys ◽  
Survey Response Rate ◽  
Significant Difference ◽  
The Impact

A 2 × 2 factorial experiment was designed to test the impact on mail survey response rate resulting from variations in paper trim size and number of printed pages in the questionnaire. ANOVA findings suggest 8½ × 11″ paper trim size produces a better response rate than an 8½ × 14″ paper trim size. Use of a one-sheet (front and back) versus a two-sheet (front only) questionnaire did not cause a significant difference in response rate; a hypothesized interaction effect was not found to be statistically significant.

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1996 ◽  
Vol 14 (7) ◽  
pp. 2083-2090 ◽  
Author(s):  
J J Rusthoven ◽  
I C Quirt ◽  
N A Iscoe ◽  
P B McCulloch ◽  
K W James ◽  
...  
Keyword(s):  
Placebo Group ◽  
Metastatic Melanoma ◽  
Response Rate ◽  
Controlled Trial ◽  
Response Rates ◽  
Poor Performance Status ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Tamoxifen Group ◽  
Significant Difference

PURPOSE We designed and conducted a randomized, double-blind, placebo-controlled trial to compare the response rates and survival of patients with metastatic melanoma who received carmustine (BCNU), dacarbazine (DTIC), and cisplatin with tamoxifen, or the same chemotherapy with placebo. PATIENTS AND METHODS Eligible patients with metastatic melanoma received either BCNU 150 mg/m2 intravenously (i.v.) on day 1, DTIC 220 mg/m2 i.v. daily on days 1 to 3 and on days 22 to 24, and cisplatin 25 mg/m2 i.v. daily on days 1 to 3 and on days 22 to 24 with placebo every 6 weeks, or the same chemotherapy with tamoxifen 160 mg orally daily for 7 days before chemotherapy and 40 mg orally daily throughout the remainder of the treatment cycle. Patients were treated on protocol for up to three cycles depending on the type of response. Assuming that a minimum increase in response rate of 20% would be necessary to conclude that tamoxifen conferred a clinically important benefit, we designed the study with an 80% chance of detecting that difference at the 5% level (two-sided). RESULTS Between February 1992 and January 1995, 211 patients were accrued, 199 of whom were considered assessable for response and toxicity. The overall response rate was 21% in the placebo group and 30% in the tamoxifen group (P = .187). Complete and partial responses were 3% and 27%, respectively, for the tamoxifen group and 6% and 14%, respectively, for the placebo group. Poor performance status and liver involvement were associated with a reduced likelihood to respond to treatment. Major toxicities were similar in both groups with no statistically significant difference in the rates of deep vein thrombosis, pulmonary thromboembolus, grade 4 neutropenia, or grade 4 thrombocytopenia. CONCLUSION These results demonstrate that the addition of high doses of tamoxifen to this chemotherapy regimen does not increase the response rate compared with chemotherapy alone in unselected patients with metastatic melanoma.

scholarly journals Superior Response Rates for Patients with Myeloid Malignancies Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC +/- Carboplatin or ATO

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3775-3775
Author(s):  
Patricia L. Kropf ◽  
Philip A. Pancari ◽  
Henry Fung ◽  
Hagop M. Kantarjian ◽  
Lianchun Xiao ◽  
...  
Keyword(s):  
Arsenic Trioxide ◽  
Phase Ii ◽  
Response Rate ◽  
Single Agent ◽  
Response Rates ◽  
Epigenetic Therapy ◽  
Adaptive Randomization ◽  
Epigenetic Effects ◽  
Significant Difference ◽  
Grade 3

Abstract Background: Epigenetic therapy is the mainstay of treatment for patients with advanced myelodysplastic syndromes (MDS) and for patients with acute myeloid leukemia (AML) who are not candidates for intense chemotherapy. Decitabine (DAC) is an FDA approved hypomethylating agent for the treatment of MDS and has clinical activity in AML. Despite DAC's activity in MDS and AML, the duration of response is limited, and once patients relapse the prognosis is poor. In pre-clinical studies, we identified potent epigenetic effects of arsenic trioxide (ATO) alone and in combination with DAC, and also found that carboplatin (Carbo) can enhance gene reactivation by DAC. We therefore initiated a randomized phase 2 clinical trial (NCT02188706) to compare the safety and efficacy of DAC in combination with either Carbo or ATO as compared to single agent DAC in patients with MDS and AML. Methods: Patients with MDS INT-1 or above or patients with AML that was relapsed or refractory or considered unfit for intense chemotherapy based on age (>60 years), poor performance status (PS2) or comorbidities were randomized to one of three regimens: DAC 20 mg/m2 days 1-5, DAC as above and Carbo AUC 5 on day 8, or DAC as above and ATO 0.15 mg/kg days 1-5. We used adaptive randomization based on response rate, and the adaptive randomization started after 10 patients were randomized to each arm equally. Cycles were scheduled every 28 days for a minimum of 4 cycles. Dose reductions/delays were allowed based on response and tolerability. Patients remained on treatment as long as they continued to benefit without toxicity. The primary endpoint was the composite response rate: the complete and partial response rates using the modified IWG 2006 criteria in MDS and IWG 2003 criteria in AML. Secondary endpoints included survival (median, one year), safety and an evaluation of the epigenetic effects of each arm. Results: 42 patients have been enrolled on study as of August 2015 (22 AML and 20 MDS). Median age was 65 years (range, 30 to 85 years). There was no statistically significant difference in patients' characteristics between the three arms. Twenty-three (60%) of the patients were previously treated and had relapsed/refractory disease. 38 patients were evaluable for response (13 on DAC alone, 11 on DAC/Carbo and 14 on DAC/ATO). There was not a significant difference in toxicity between the arms, with Grade 3 neutropenia and Grade 3 thrombocytopenia as the most common side effects. Responses (CR, Cri, PR) were seen in 3/13 patients on DAC alone (23%), 5/11 patients on DAC/Carbo (45%, p=0.18 compared to DAC alone) and 10/14 patients on DAC/ATO (71%, p=0.01 compared to DAC alone). Responses in treatment naïve patients were seen in 3/7 patients with DAC alone, 2/4 patients with DAC/Carbo and 6/6 patients with DAC/ATO. Fitting a logistic regression model comparing treatments accounting for whether the patients had received prior therapy, the DAC/ATO arm showed a statistically higher response rate as compared to DAC alone (p=0.02). Conclusion: In this randomized phase II study, we find that the combination of decitabine and arsenic trioxide is well tolerated and yields a higher response rate compared to decitabine alone or to decitabine/carboplatin. Our results warrant further studies comparing these regimens for patients with MDS and AML. Disclosures Kropf: Teva Pharmaceuticals: Consultancy. Issa:Astex: Consultancy.

scholarly journals A Prospective Cohort Study of Vitamin D Supplementation in AD Soldiers: Preliminary Findings

2019 ◽  
Vol 184 (Supplement_1) ◽  
pp. 498-505
Author(s):  
Mary S McCarthy ◽  
Evelyn B Elshaw ◽  
Barbara M Szekely ◽  
Dheeraj Raju
Keyword(s):  
Vitamin D ◽  
Prospective Trial ◽  
Sun Exposure ◽  
Vitamin D Supplementation ◽  
Measurement Information ◽  
High Dose ◽  
Metabolic Dysfunction ◽  
Vitamin D Status ◽  
Significant Difference ◽  
Patient Reported

Abstract Purpose To explore response to vitamin D supplementation in active duty (AD) warfighters and translate findings into evidence-based health policy. Background Soldiers are at risk for musculoskeletal injuries and metabolic dysfunction that impact physical performance and military readiness; the link with low vitamin D status is unclear. Methods This prospective trial enrolled 152 soldiers; baseline 25 hydroxyvitamin (OH) D level determined assignment to a no-treatment control (CG) or treatment group (TG) receiving a vitamin D3 supplement for 90 days. Symptoms, diet, sun exposure, and blood biomarkers obtained at baseline (T1) and 3 months (T2). Results Cohort was predominantly white (58%) with a significant difference in racial distribution for vitamin D status. Mean (SD) 25(OH)D levels were 37.8 (5.6) ng/mL, 22.2 (5.0) ng/mL, and 22.9 (4.7) ng/mL for the CG, low dose TG, and high-dose TG at T1, respectively. Following three months of treatment, one-way ANOVA indicated a statistically significant difference between groups (F5,246 = 44.37; p &lt; 0.0001). Vitamin D intake was 44% of Recommended Dietary Allowance throughout the first phase of the trial. Patient-Reported Outcomes Measurement Information System scores improved in TG for fatigue and sleep, p &lt; 0.01. Conclusions Vitamin D deficiency is widespread in AD soldiers. Clinicians must intervene early in preventable health conditions impacting warfighter performance and readiness and recommend appropriate self-care strategies.

The association between pre-operative patient-reported health and post-arthroplasty health survey response rates: a registry-based cohort study. (Preprint)

2021 ◽  
Author(s):  
Ian Harris ◽  
Yi Peng ◽  
Ilana Ackerman ◽  
Steven E Graves
Keyword(s):  
Health Status ◽  
Knee Arthroplasty ◽  
Response Rate ◽  
Response Rates ◽  
Post Surgery ◽  
Utility Index ◽  
Significant Difference ◽  
Patient Reported ◽  
Response Status ◽  
Hip And Knee Arthroplasty

BACKGROUND Patient reported outcome measures (PROMs) are commonly used to report outcomes after hip and knee arthroplasty but response rates are rarely complete. Given that pre-operative health status (as measured by PROMs) is a strong predictor of outcomes (using the same measures) and that these outcomes may influence the response rate, it is possible that post-operative response rates may be influenced by pre-operative health status. OBJECTIVE This study aims to test the association between pre-operative PROMs and post-operative response status following hip and knee arthroplasty. METHODS Data from the PROMs program of a large national registry were used. Pre-operative PROMs were the Oxford Hip Score or Oxford Knee Score, EQ5D Utility Index and the EQ visual analogue scale (VAS) for overall health. Logistic regression, adjusting for age, sex, body mass index (BMI) and American Society of Anesthesiologists (ASA) Physical Status Classification System, was used to test the association between each pre-operative PROM and response status for the 6-months post-surgery survey. RESULTS Data from 9,499 and 16,539 patients undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA) for osteoarthritis, respectively, were included in the analysis. Adjusting for age, sex, BMI and ASA, there was no significant difference in response status at 6 months based on the pre-operative Oxford Hip or Knee Scores (OR 1.00, 95% CI 0.99 to 1.01 for both, p = 0.70 for THA, p = 0.85 for TKA). Healthier patients (based on the EQ VAS scores) pre-operatively were more likely to respond at 6 months, but this difference was negligible (OR 1.00, 95% CI 1.00 to 1.01 for THA and TKA, p = 0.004 for THA, p < 0.001 for TKA). Pre-operative EQ Utility Index was not associated with response rate at 6 months for THA (OR 1.14, 95% CI 0.96 to 1.36, p = 0.13) or TKA patients (OR 1.05, 95% CI 0.91 to 1.22, p = 0.49). CONCLUSIONS Patients who respond to PROMs surveys at 6 months post THA and TKA demonstrated similar pre-operative PROMs scores to those who did not respond. This can allay concerns that differences in pre-operative pain, function and quality of life might introduce bias when assessing surgical outcomes where there is loss to follow-up post-operatively.

Effectiveness of “Begging” as a Persuasive Tactic for Improving Response Rate on a Client/Agency Mail Survey

1996 ◽  
Vol 78 (1) ◽  
pp. 204-206 ◽  
Author(s):  
Michael L. Maynard
Keyword(s):  
Experimental Study ◽  
Treatment Group ◽  
Response Rate ◽  
Mail Survey ◽  
Response Rates ◽  
Mail Surveys ◽  
Significant Difference ◽  
Job Function

This experimental study tested the assumption that ingratiation through the researcher's frank request for compliance yields higher response rates to mail surveys. The hypothesis was tested by inserting a cartoon of the researcher “begging” the recipient within the treatment group to respond. Results suggest that begging achieved a reduction in nonresponse within the treatment group ( n = 116). Also, begging made no significant difference along the dimensions of job function, gender, or seniority.

Sign in / Sign up

Export Citation Format

Share Document